Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1400322
European Journal of Endocrinology, Vol 140, Issue 4, 322-327
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bisi, G
Right arrow Articles by Ghigo, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bisi, G
Right arrow Articles by Ghigo, E

Clinical Studies

Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults

G Bisi, V Podio, MR Valetto, F Broglio, G Bertuccio, G DEl Rio, MF Boghen, F Berti, EE Muller, and E Ghigo

Division of Nuclear Medicine and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy.

OBJECTIVE: IGF-I possesses specific myocardial receptors and is able to promote cardiac remodelling and even inotropic effects in both humans and other animals. In fact, reduced cardiac mass and performance are present in GH deficiency and these alterations are counteracted by recombinant human (rh) GH replacement, restoring IGF-I levels. Recently, the acute administration of 60 microg/kg rhIGF-I has also been reported to be able to improve cardiac performance evaluated by echocardiography or impedance cardiography in normal subjects. The aim of our study was to verify the effects of a subcutaneous low dose of rhIGF-I (20 microg/kg) on cardiac performance in humans. METHODS: In six healthy male adults (mean+/-S. e.m.: 35.7+/-4.3 years of age), the effects of rhIGF-I on left ventricular function evaluated by radionuclide angiocardiography and on circulating IGF-I, GH, insulin, glucose and catecholamines levels were studied. RESULTS: Administration of rhIGF-I increased circulating IGF-I (peak at +150 min vs baseline: 330.2+/- 9.6 vs 199. 7+/-8.7 microg/l, P<0.03) to levels which persisted similarly up to +180min. Neither GH nor catecholamine levels were modified by rhIGF-I administration, while insulin and glucose levels showed a slight but significant decrease. Basal left ventricular ejection fraction (61.8+/-2.0%) significantly increased at +180 min after rhIGF-I (65.3+/-2.7%, P<0.03). No change was recorded in mean blood pressure while a non-significant trend towards a reduction of heart rate was present by +120 min. CONCLUSIONS: These findings indicate that even subcutaneous administration of a low dose of rhIGF-I has acute inotropic effects as evaluated by radionuclide angiocardiography in healthy adults.


This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio
A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both?
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244.
[Abstract] [PDF]


Home page
HeartHome page
A-A Kotlyar, Z Vered, I Goldberg, P Chouraqui, D Nas, E Fridman, Z Chen-Levy, S Fytlovich, G Sangiorgi, L G Spagnoli, et al.
Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine
Heart, December 1, 2001; 86(6): 693 - 700.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.